Increased hospital case volume is associated with improved survival and quality of care for uterine corpus cancer in Belgium
On average, increased hospital case volume was positively associated with improved overall survival and quality of care, supporting centralization of uterine corpus cancer care into high-volume reference centers in Belgium.
Authors
- Evert de Jonge (ORCID: https://orcid.org/0000-0003-1431-8039)
- Geert Silversmit (ORCID: https://orcid.org/0000-0003-1104-1839)
- Hannelore Denys (ORCID: https://orcid.org/0000-0002-8897-9430)
- Frédéric Goffin (ORCID: https://orcid.org/0000-0001-9327-9204)
- Nancy Van Damme (ORCID: https://orcid.org/0000-0003-4636-7636)
- Alejandro Herreros‐Pomares (ORCID: https://orcid.org/0000-0003-3838-097X)
- Gerd Jacomen
- Anke De Geyndt
- Joren Vanbraband (ORCID: https://orcid.org/0000-0003-0180-0942)
- Gauthier Bouche (ORCID: https://orcid.org/0000-0002-3407-2788)
Institutions
- Ghent University Hospital (BE)
- Ziekenhuis Oost-Limburg (BE)
- Centre hospitalier régional de la Citadelle (BE)
- AZ Sint-Lucas (BE)
- Anticancer Fund (BE)
- KU Leuven (BE)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1016/j.ijgc.2025.102849
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Teva Pharmaceutical Industries
- Seagen
- Kom op tegen Kanker
- PharmaMar
- LEO Pharma
- Daiichi Sankyo Europe